title: [Window of opportunity for treatment of rheumatoid arthritis].
abstract: Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology characterized by symmetric, erosive synovitis. Joints become eroded in the first 2 years of early RA. But the subsequent course of radiological progression is highly variable and cannot be easily explained. Their disability correlates with signs and symptoms of inflammation and it correlates more closely with articular damage. TNF blockers (infliximab and etanercept) affect signs and symptoms as well as radiographic progression of RA. They are among the most effective therapies for RA. Early diagnosis and early appropriate treatment of RA are thought to be key to controlling progress of disease and preventing further joint and tissue damage. The concept of "window of opportunity" exists from the notion that early institution of therapy for RA is more effective in preventing joint damage, decreasing functional disability, and inducing clinical remission.
authors.affiliation: Center for Rheumatic Diseases, Kurume University Medical Center.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Fukuda
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D042241:Early Diagnosis; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate